This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prince, H. E.
Right arrow Articles by Hogrefe, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prince, H. E.
Right arrow Articles by Hogrefe, W. R.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, September 2003, p. 764-768, Vol. 10, No. 5
1071-412X/03/$08.00+0     DOI: 10.1128/CDLI.10.5.764-768.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Detection of West Nile Virus (WNV)-Specific Immunoglobulin M in a Reference Laboratory Setting during the 2002 WNV Season in the United States

Harry E. Prince* and Wayne R. Hogrefe

Focus Technologies, Cypress, California 90630

Received 5 May 2003/ Returned for modification 20 June 2003/ Accepted 25 June 2003

Between 1 June and 31 December 2002, 30,677 serum samples and 4,554 cerebrospinal fluid (CSF) samples were tested for West Nile virus (WNV)-specific immunoglobulin M (IgM) by an in-house enzyme-linked immunosorbent assay (ELISA); 1,481 serum samples (4.8%) and 345 CSF samples (7.6%) were positive for WNV IgM. Positive samples were forwarded to public health service laboratories (PHSLs) for further testing. PHSLs supplied results from their WNV IgM ELISAs for 654 samples; 633 (97%) were positive. PHSLs supplied WNV plaque reduction neutralization test results for 128 samples; 123 (96%) were positive. WNV IgM seroconversion and seroreversion trends were evaluated for 749 patients who each provided two serum samples that were tested during the study period. Of 574 patients whose first serum sample was IgM negative, 41 (7%) seroconverted (the second serum sample was IgM positive); of 175 patients whose first serum sample was IgM positive, 22 (13%) seroreverted (the second serum sample was IgM negative). The seroreversion rate was directly proportional to the time between serum sample collection; whereas only 1% of patients whose sera were collected <20 days apart showed seroreversion, 54% of patients whose sera were collected >60 days apart showed seroreversion. Conversion and reversion trends for CSF were evaluated for 68 patients. Of 54 patients whose first CSF specimen was IgM negative, 9 (17%) converted; none of 14 patients whose first CSF specimen was IgM positive reverted. Concomitant detection of WNV IgM in serum and CSF was assessed for 1,188 patients for whom paired serum and CSF specimens were available; for all 130 patients for whom IgM was detectable in CSF, IgM was also detectable in serum. These findings show that an in-house WNV IgM ELISA accurately identifies patients with WNV infection, document WNV IgM conversion and reversion trends, and demonstrate that WNV IgM detection in CSF is accompanied by WNV IgM detection in serum.

* Corresponding author. Mailing address: Focus Technologies, 5785 Corporate Ave., Cypress, CA 90630. Phone: (714) 503-2047. Fax: (714) 484-1296. E-mail: hprince{at}focustechnologies.com.

Clinical and Diagnostic Laboratory Immunology, September 2003, p. 764-768, Vol. 10, No. 5
1071-412X/03/$08.00+0     DOI: 10.1128/CDLI.10.5.764-768.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Prince, H. E., Tobler, L. H., Lape-Nixon, M., Foster, G. A., Stramer, S. L., Busch, M. P. (2005). Development and Persistence of West Nile Virus-Specific Immunoglobulin M (IgM), IgA, and IgG in Viremic Blood Donors. J. Clin. Microbiol. 43: 4316-4320 [Abstract] [Full Text]  
  • Prince, H. E., Lape-Nixon, M. (2005). Evaluation of a West Nile Virus Immunoglobulin A Capture Enzyme-Linked Immunosorbent Assay. CVI 12: 231-233 [Abstract] [Full Text]  
  • Crichlow, R., Bailey, J., Gardner, C. (2004). Cerebrospinal Fluid Neutrophilic Pleocytosis in Hospitalized West Nile virus Patients. J Am Board Fam Med 17: 470-472 [Abstract] [Full Text]  
  • Hogrefe, W. R., Moore, R., Lape-Nixon, M., Wagner, M., Prince, H. E. (2004). Performance of Immunoglobulin G (IgG) and IgM Enzyme-Linked Immunosorbent Assays Using a West Nile Virus Recombinant Antigen (preM/E) for Detection of West Nile Virus- and Other Flavivirus-Specific Antibodies. J. Clin. Microbiol. 42: 4641-4648 [Abstract] [Full Text]  
  • Purdy, D. E., Noga, A. J., Chang, G.-J. J. (2004). Noninfectious Recombinant Antigen for Detection of St. Louis Encephalitis Virus-Specific Antibodies in Serum by Enzyme-Linked Immunosorbent Assay. J. Clin. Microbiol. 42: 4709-4717 [Abstract] [Full Text]  
  • Muerhoff, A. S., Dawson, G. J., Dille, B., Gutierrez, R., Leary, T. P., Gupta, M. C., Kyrk, C. R., Kapoor, H., Clark, P., Schochetman, G., Desai, S. M. (2004). Enzyme-Linked Immunosorbent Assays Using Recombinant Envelope Protein Expressed in COS-1 and Drosophila S2 Cells for Detection of West Nile Virus Immunoglobulin M in Serum or Cerebrospinal Fluid. CVI 11: 651-657 [Abstract] [Full Text]  
  • Prince, H. E., Lape'-Nixon, M., Moore, R. J., Hogrefe, W. R. (2004). Utility of the Focus Technologies West Nile Virus Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assay for Testing Cerebrospinal Fluid. J. Clin. Microbiol. 42: 12-15 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»